| Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, MJ Blaha, S Dai, ... Circulation 129 (3), e28-e292, 2014 | 19007* | 2014 |
| 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Task Force Members, G Montalescot, U Sechtem, S Achenbach, ... European heart journal 34 (38), 2949-3003, 2013 | 5955 | 2013 |
| Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JL Mega, T Simon, JP Collet, JL Anderson, EM Antman, K Bliden, ... Jama 304 (16), 1821-1830, 2010 | 1510 | 2010 |
| Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study JP Collet, JS Hulot, A Pena, E Villard, JB Esteve, J Silvain, L Payot, ... The Lancet 373 (9660), 309-317, 2009 | 1298 | 2009 |
| Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects JS Hulot, A Bura, E Villard, M Azizi, V Remones, C Goyenvalle, M Aiach, ... Blood 108 (7), 2244-2247, 2006 | 1279 | 2006 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update SA Scott, K Sangkuhl, CM Stein, JS Hulot, JL Mega, DM Roden, TE Klein, ... Clinical Pharmacology & Therapeutics 94 (3), 317-323, 2013 | 1133 | 2013 |
| Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial P Lechat, JS Hulot, S Escolano, A Mallet, A Leizorovicz, ... Circulation 103 (10), 1428-1433, 2001 | 715 | 2001 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy SA Scott, K Sangkuhl, EE Gardner, CM Stein, JS Hulot, JA Johnson, ... Clinical Pharmacology & Therapeutics 90 (2), 328-332, 2011 | 650 | 2011 |
| Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy JS Hulot, X Jouven, JP Empana, R Frank, G Fontaine Circulation 110 (14), 1879-1884, 2004 | 595 | 2004 |
| Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19* 2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta … JS Hulot, JP Collet, J Silvain, A Pena, A Bellemain-Appaix, O Barthélémy, ... Journal of the American College of Cardiology 56 (2), 134-143, 2010 | 537 | 2010 |
| Statin therapy is associated with lower prevalence of gut microbiota dysbiosis S Vieira-Silva, G Falony, E Belda, T Nielsen, J Aron-Wisnewsky, ... Nature 581 (7808), 310-315, 2020 | 489 | 2020 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update CR Lee, JA Luzum, K Sangkuhl, RS Gammal, MS Sabatine, CM Stein, ... Clinical pharmacology & therapeutics 112 (5), 959-967, 2022 | 476 | 2022 |
| Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European … J Čelutkienė, R Pudil, T Lopez-Fernandez, J Grapsa, P Nihoyannopoulos, ... European journal of heart failure 22 (9), 1504-1524, 2020 | 453 | 2020 |
| Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial KT Ong, J Perdu, J De Backer, E Bozec, P Collignon, J Emmerich, ... The Lancet 376 (9751), 1476-1484, 2010 | 441 | 2010 |
| AHA statistical update AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, MJ Blaha, S Dai, ... Circulation 127, e62-e245, 2013 | 397 | 2013 |
| Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association … R Pudil, C Mueller, J Čelutkienė, PA Henriksen, D Lenihan, S Dent, ... European journal of heart failure 22 (11), 1966-1983, 2020 | 396 | 2020 |
| Feasibility and safety of ultrasound-aided thoracentesis in mechanically ventilated patients D Lichtenstein, JS Hulot, A Rabiller, I Tostivint, G Mezière Intensive care medicine 25 (9), 955-958, 1999 | 386 | 1999 |
| Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses H Pan, R Peto, AMH Restrepo, MP Preziosi, V Sathiyamoorthy, QA Karim, ... The Lancet 399 (10339), 1941-1953, 2022 | 378 | 2022 |
| Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus N Costedoat‐Chalumeau, Z Amoura, JS Hulot, HA Hammoud, G Aymard, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2006 | 342 | 2006 |
| Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure … C Maack, M Lehrke, J Backs, FR Heinzel, JS Hulot, N Marx, WJ Paulus, ... European heart journal 39 (48), 4243-4254, 2018 | 315 | 2018 |
